J Korean Cancer Assoc.  1999 Aug;31(4):773-783.

Effects of New Nultidrug - Resistance Reversing Agent, KR-30035, on Tumoral Uptake of Tc-99m MIBI In-vitro and In-vivo

Affiliations
  • 1Department of Nuclear Medicine, School of Medicine Kyungpook National University, Taegu, Korea.
  • 2Cancer Research Institute, School of Medicine Kyungpook National University, Taegu, Korea.
  • 3Bioorganic Science Division Korea Institute of Chemical Technology, Taejon, Korea.
  • 4Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea.

Abstract

PURPOSE: Verapamil is one of the most extensively characterized modulators of P-glyco- protein (P-gp) mediated multi-drug resistance (MDR), but its plasma concentration required to reverse MDR can cause cardiovascular toxicity. KR-30035 is a newly synthesized verapamil analogue with more potent cytostatic effects, but has lower cardiovascular effects than verapamil. We have assessed the MDR reversing effects of KR-30035 by measuring Tc-99m MIBI uptake in cultured tumor cells and in nude mice bearing human tumor xenografts.
MATERIALS AND METHODS
In-vitro uptake of Tc-99m MIBI was measured in murine leukemia cells (L-1210) and those MDR-positive variants after incubation with different concentrations of KR-30035. Results were compared to those with verapamil. Organ and tumoral uptake of Tc-99m MIBI was compared between P-gp (+) human colon cancer (HCT15 cells) and P-gp (-) lung cancer (A549 cells) in nude mice, treated with either KR-30035 or verapamil.
RESULTS
There was no significant difference in in-vitro uptake of Tc-99m MIBI between verapamil and KR-30035 group at any concentrations. MIBI uptake in P-gp (+) cells continuously increased either with verapamil or KR-30035 in a dose-dependent manner. Tc-99m MIBI uptake ratios of the tumor [P-gp (+' tumor uptake divided by P-gp (-) uptake] were significantly higher with KR-30035 than with verapamil in tumor bearing nude mice. Washout rate of Tc-99m MIBI from P-gp (+) HCT15 cells was lower in verapamil or KR-30035 groups than in the control group, which was 0.19, 0.19 and 0.27 respectively.
CONCLUSION
These studies revealed that KR-30035 can potentially be used as an active modulator of MDR, with its significantly lesser cardiovascular toxicity than verapamil. Our results warrants further evaluation of this novel agent.

Keyword

KR-30035; Verapamil; Multi-drug resistance; Tc-99m MIBI

MeSH Terms

Animals
Colonic Neoplasms
Drug Resistance, Multiple
Heterografts
Humans
Leukemia
Lung Neoplasms
Mice
Mice, Nude
P-Glycoprotein
Plasma
Robenidine
Tumor Cells, Cultured
Verapamil
P-Glycoprotein
Robenidine
Verapamil
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr